Latest News and Press Releases

Groundbreaking Study Demonstrates Safety and Tolerability of Oral Mucosal Immunotherapy (OMIT) for Peanut Allergy Using Toothpaste

Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events

Intrommune Therapeutics today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board.

OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects

Washington, DC, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) issued the following statement which may be attributed to Kenneth Mendez, president and CEO:  ...

New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Allergy Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ResearchAndMarkets.com's...

Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy

Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Global Peanut Allergy Treatment Market Size, Share & Trends Analysis Report by Drug Class (Antihistamines, Epinephrine), Route Of Administration,...

Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy